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AbsTrACT
Introduction Limited data exist on Clostridium difficile 
infection (CDI) in low-resource settings and settings with 
high prevalence of HIV. We aimed to determine baseline 
CDI patient characteristics and management and their 
contribution to mortality.
Methods We reviewed adult patients hospitalised with 
diarrhoea and a C. difficile test result in 2015 from four 
public district hospitals in the Western Cape, South Africa. 
The primary outcome measures were risk factors for 
mortality. Secondary outcomes were C. difficile risk factors 
(positive vs negative) and CDI treatment.
results Charts of patients with diarrhoea tested for C. 
difficile (n=250; 112 C. difficile positive, 138 C. difficile 
negative) were reviewed. The study population included 
more women (65%). C. difficile-positive patients were 
older (46.5 vs 40.7 years, p<0.01). All-cause mortality was 
more common in the C. difficile-positive group (29% vs 
8%, p<0.0001; HR 2.0, 95% CI 1.1 to 3.6). Tuberculosis 
(C. difficile positive 54% vs C. difficile negative 32%, 
p<0.001), 30-day prior antibiotic exposure (C. difficile 
positive 83% vs C. difficile negative 46%, p<0.001) and 
prior hospitalisation (C. difficile positive 55% vs C. difficile 
negative 22%, p<0.001) were also more common in the 
C. difficile-positive group. C. difficile positive test result 
(OR 4.7, 95% CI 2.0 to 11.2; p<0.001), male gender (OR 
2.8, 95% CI 1.1 to 7.2; p=0.031) and tuberculosis (OR 
2.3, 95% CI 1.0 to 5.0; p=0.038) were independently 
associated with mortality. Of patients starting treatment, 
metronidazole was the most common antimicrobial 
therapy initiated (70%, n=78); 32 C. difficile-positive (29%) 
patients were not treated.
Conclusion Patients testing positive for C. difficile are at 
high risk of mortality at public district hospitals in South 
Africa. Tuberculosis should be considered an additional 
risk factor for CDI in populations with high tuberculosis 
and HIV comorbidity. Interventions for CDI prevention and 
management are urgently needed.
InTroduCTIon
Clostridium difficile infection (CDI) is an 
increasing global health concern resulting in 
severe diarrhoea, excessive healthcare costs, 
readmissions and mortality. Life-threatening 
complications resulting from CDI include 
sepsis, pseudomembranous colitis and toxic 
megacolon. The majority of CDI studies 
have been conducted in high-resource coun-
tries.1 CDI incidence increased yearly in these 
settings after 2000 until recently; a decline 
in CDI incidence from 2011 to 2015 in long-
term care settings was reported in association 
with decreased hospital fluoroquinolone use 
and detection of the NAP1/027 strain.1 2 C. 
difficile remains the most common pathogen 
Key questions
What is already known?
 ► Patients in South Africa have significant comorbidi-
ties distinct from high-resource countries, including 
a higher incidence of HIV and tuberculosis, which 
may uniquely increase patients’ risk for Clostridium 
difficile infection (CDI).
What are the new findings?
 ► This study is the first examining risk factors, man-
agement, infection control and mortality among hos-
pitalised patients in public hospitals in sub-Saharan 
Africa to our knowledge.
 ► The majority of patients treated for CDI received 
metronidazole, while the mortality of patients with 
a C. difficile positive result was significantly higher 
than similar patients testing negative with diarrhoea.
 ► In populations with high tuberculosis and HIV comor-
bidity, tuberculosis is an additional risk factor for CDI.
What do the new findings imply?
 ► Vancomycin should be considered as an alternative 
to metronidazole in populations with high prevalence 
of tuberculosis and immunocompromising condi-
tions as a high mortality rate was observed in this 
study.
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implicated in hospital-acquired infections in the USA.3 4 
CDI in patients is associated with antibiotic use, which 
leads to disruption of normal flora and uninhibited growth 
of toxigenic C. difficile.5 Antibiotics commonly associated 
with CDI include fluoroquinolones, third-generation 
cephalosporins, clindamycin and penicillins.6 Advanced 
age is a noted risk factor for CDI, and commonly asso-
ciated with CDI mortality in high-resource countries.7 
Additional risk factors for CDI include hospitalisation, 
inflammatory bowel disease, immunodeficiency, organ 
transplantation, chemotherapy, gastric acid suppression, 
chronic kidney disease and exposure to individuals with 
C. difficile.6 The healthcare environment and patients 
in low-resource settings are distinct from high-resource 
settings. For example, South Africa has the lowest life 
expectancy in the world, 49.7 years, reducing the likeli-
hood for elderly age to be a CDI risk factor.8 Meanwhile, 
the relationship of CDI and the infectious diseases asso-
ciated with mortality in this population is understudied. 
Thus, further investigation of CDI risk factors in these 
countries is urgently needed.
In South Africa, the leading causes of death are infec-
tious diseases including tuberculosis, influenza/pneu-
monia and HIV, which may uniquely increase patients’ 
risk for CDI.9 10 South Africa has the largest known HIV 
epidemic in the world. Adult prevalence is estimated to 
be 18.9%, and 19% of people living with HIV globally 
reside in South Africa.11 Tuberculosis incidence in South 
Africa is the sixth highest globally. Coinfection of tuber-
culosis in patients with HIV is a synergistic epidemic, 
including a disproportionate rate of HIV-associated 
tuberculosis deaths as 63% of tuberculosis cases are in 
patients with HIV.12 13 Over the past decade, tubercu-
losis has surpassed HIV and cardiovascular disease as the 
leading cause of death.14 While CDI studies in Africa are 
limited, two previous studies at a tertiary hospital in Cape 
Town, South Africa, documented 9%–22% of patients 
with diarrhoea tested C. difficile positive using different 
methods.15 16 In one of these studies, patients with C. 
difficile positive results were associated with antibiotic 
use in the previous 28 days and hospitalisation within 
the previous 90 days compared with patients with nega-
tive results.15 The prevalence of the NAP1/027 strain was 
3.4%, which is substantially lower than in high-resource 
settings such as the USA, which has ranged from a 16.9% 
to 26.2% prevalence in recent studies.15 17
Understanding the epidemiology of CDI in low-re-
source settings is essential to improve identification, 
prevention and treatment measures. In the present study, 
we identify patient CDI characteristics and management 
in resource-limited public district level hospitals and 
their contribution to mortality.
MeTHods
Local infectious disease leaders were consulted early 
in study design, starting in August 2015. These leaders 
identified CDI as a critical public health challenge in 
South Africa because of its increasing incidence and high 
morbidity and mortality globally, lack of local studies and 
vulnerable populations with HIV and tuberculosis locally. 
In addition to the lack of CDI studies performed in these 
hospitals and this patient population, focus on district 
hospitals was also recommended due to the scarcity of 
CDI data at this level. Subsequently the University of 
the Western Cape Research Ethics Committee, National 
Health Laboratory Service (NHLS) and Western Cape 
Department of Health granted approval for the first 
CDI epidemiological study in South African district level 
hospitals.
On approval, a multicentre, retrospective chart review 
was conducted at four district-level hospitals, averaging 
265 inpatient beds, in Cape Town, South Africa. The 
study included hospitalised adult patients (>18 years of 
age) with diarrhoea and either a positive or negative C. 
difficile PCR test result from one or more stool samples 
during the year 2015. These patients were identified from 
a list of C. difficile test results provided by NHLS, which is 
a national network of diagnostic laboratories that serve 
80% of the South African population, including the 
Western Cape Department of Health hospitals. All stool 
samples from the district-level hospitals included in this 
study were sent to the NHLS laboratory at the nearest 
tertiary-level hospital. Standardised NHLS protocols indi-
cated PCR testing for all eligible samples in 2015 (NHLS 
does not perform C. difficile tests on solid stool samples 
or patients with a recent C. difficile positive result). All 
patients included in the study had diarrhoea that took 
the shape of the container and clinical suspicion for 
CDI. A minimum number of stools within 24 hours was 
not required for study inclusion as frequency was incon-
sistently documented. Any additional aetiologies tested 
were not included in the laboratory report. Test results 
originating from paediatric patients, outpatient clinics 
or day surgery patients were excluded. Patients with tests 
ordered in the emergency department were included if 
the patient was subsequently admitted to the hospital.
The primary outcome of this study was the identifica-
tion of risk factors for mortality in South African patients 
in the Western Cape with diarrhoea. Secondary outcomes 
were risk factors for a C. difficile positive result compared 
with a C. difficile negative result, and within this group, 
risk factors for mortality and management of CDI.
The 2015 medical records for any patient with a C. diffi-
cile test result were reviewed from August 2016 to April 
2017. Data collection was subject to the available 
processes for medical record review and availability 
of files at each individual hospital. Paper folders were 
requested from the medical records department at 
each hospital and reviewed by study personnel onsite. 
At one hospital, medical records were accessible elec-
tronically by access granted to view scanned files of the 
patient folders remotely. The review included all avail-
able patient records with a positive C. difficile test result. 
At each hospital, an equal number of C. difficile-positive 
and negative patient charts were requested and reviewed 
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if available. At most hospitals, the number of negative 
test results was much larger than positive results. There-
fore, all identified patients with a positive C. difficile test 
result were requested, while patients with a negative test 
result were randomly selected following an autogene-
rated random number process. The randomisation of 
the negative chart numbers was performed to address 
selection bias. If the total number of patients tested at 
each hospital was less than 25, all available charts were 
reviewed. As this is the first epidemiologic study in 
district-level hospitals, the magnitude of tests was difficult 
to predict. In this study design, the number of positive 
results limited sample size during the year evaluated and 
an a priori sample size calculation was not performed.
Use of a structured data collection tool allowed for 
review of all clinical and laboratory notes available 
in the medical record from the hospital admission 
including the C. difficile test. Pertinent records prior to 
the admission were also reviewed using the same tool 
to determine medical history and previous antibiotic 
exposure, and postadmission records were reviewed to 
determine patient outcomes, recurrence and mortality. 
Data collected included demographics (gender, age, 
allergies), comorbid conditions (HIV, tuberculosis, 
multidrug-resistant tuberculosis, diabetes, cardiovascular 
conditions: heart failure, hypertension, hyperlipidaemia, 
other cardiovascular conditions, malignancy, inflam-
matory bowel diseases: ulcerative colitis, Crohn’s, other 
immunocompromising condition), hospitalisations prior 
to the current admission (0–30 and 31–90 days prior to 
test order) and previous antibiotic exposure, including a 
single dose (penicillins, quinolones, carbapenems, ceph-
alosporin, clindamycin or other), and indication in prior 
30 and 90 days from date of written CDI order, CDI history 
(current episode is documented as first CDI episode, 
recurrence, unknown if first episode or recurrence), 
clinical presentation (diarrhoea, temperature (>38°C), 
haematochezia, pseudomembranous colitis), dates of 
admission, rehydration, loperamide use, CDI antibiotic 
treatment, CDI-related infection control (isolation and 
contact precautions) and reason for hospitalisation.
Data were analysed using Stata SE statistical soft-
ware (V.15.0, StataCorp, College Station, Texas, USA). 
Summary statistics for infection management were 
determined, including antibiotic treatment and infec-
tion prevention and control components. Length of stay 
(LOS) was summarised and compared by t-tests both by 
C. difficile test result and hospital mortality to express 
mean, median and statistically significant differences. 
Univariate summary statistics were calculated for age and 
gender of individual patients. Χ2 tests were conducted 
by C. difficile test result and mortality for patient char-
acteristics and CDI risk factors. A survival analysis with 
the Gehan-Breslow-Wilcoxon test was determined for 
patients with C. difficile positive PCR versus C. difficile 
negative PCR in GraphPad Prism (V.6, GraphPad Soft-
ware, La Jolla, California, USA), with a start date equal to 
when an order for C. difficile test was written and end date 
the day of mortality or discharge. Censoring occurred for 
patients discharged before 30 days to account for uncer-
tainty of survival and readmission after discharge. Patients 
with a clinic visit or hospital admission occurring greater 
than 30 days after the C. difficile test were categorised 
as survivors. P values ≤0.05 were considered significant. 
All variables identified as at least marginally significant 
(p<0.10) predictors in the univariate mortality analysis 
were included in the model. Independent predictors of 
all-cause mortality were determined via a separate multi-
variable logistic regression.
resulTs
Overall, 652 C. difficile PCR tests were conducted in 
2015 from the four hospitals included; 19 of these had 
an error result and were excluded. Forty-one of the 291 
patient charts requested were excluded because either 
the patient chart was unavailable or missing, the chart 
lacked adequate documentation to review related to 
the test date, or the test met exclusion criteria for not 
occurring during a hospitalisation (eg, outpatient clinic, 
day surgery). Of 139 positive results, 112 results and 
corresponding charts were reviewed and of 494 negative 
results, 138 negative results were reviewed (total n=250; 
figure 1). Two tests were reviewed for one patient during 
a 76-day LOS. All other test results reviewed were from 
unique hospitalisations. The 250 test results reviewed 
represent 225 individual patients.
Patient characteristics analysed by test result in the 
univariate analyses are presented in table 1. Significant 
differences were found in the patient demographics in 
patients testing positive versus negative for C. difficile 
including age, tuberculosis, prior hospitalisation and 
specific antibiotic use. Mean age and gender distribution 
was calculated for 225 individual patients (102 C. diffi-
cile+; 123 C. difficile−), excluding subsequent test results 
from patients with more than one test in the study period. 
The mean age for the C. difficile-positive patients was 
46.5 years compared with 40.7 years for C. difficile-nega-
tive patients (p<0.01). There were more women in the 
study population (65%). However, mean age was similar 
between men and women in this study overall (43.4 vs 
43.3 years, respectively).
Presence of comorbid infectious diseases also proved 
to be a significant variable, particularly with regard to 
tuberculosis. More patients testing positive for C. difficile 
also had tuberculosis (C. difficile positive 54% vs C. diffi-
cile negative 32%, p<0.001). HIV rates were high in both 
C. difficile-positive and C. difficile-negative patients (71% 
vs 80%, respectively; p=0.07). Of HIV-positive patients 
with a C. difficile test result, the majority had CD4 counts 
consistent with AIDS (CD4 <0.2 x10^9 cells/L ; C. difficile 
positive 81%; C. difficile negative 81%; n=178).
Analysis of C. difficile test results confirmed prior hospi-
talisation and antibiotic exposure are important CDI risk 
factors among patients included in the study. Recent prior 
hospitalisation was more common in C. difficile-positive 
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patients for both hospitalisation 30 and 90 days prior 
to the admission (p<0.001). Thirty-day prior antibiotic 
exposure to all antibiotic classes reviewed was signifi-
cantly higher in the C. difficile-positive group (table 1). 
The most common antibiotic class with recent prior 
exposure to patients tested for C. difficile was cephalospo-
rins, with half of C. difficile-positive patients receiving a 
cephalosporin in the 30 days prior to the C. difficile test 
order (vs 34% in C. difficile negative, p<0.02). Docu-
mentation of tuberculosis antibiotic treatment prior to 
admission was insufficient to report as prior tuberculosis 
treatment was not consistently detailed for patients with 
treatment ordered in hospital. Prescriptions outside the 
hospital and onsite clinic were not captured if not noted 
in the admission clinical notes.
Mortality in patients with diarrhoea was more common 
in the C. difficile-positive group (29% vs 8%, p<0.0001). 
A Kaplan-Meier survival analysis (p=0.0087) for patients 
evaluated following a C. difficile test order (figure 2) 
found an all-cause mortality HR of 2.0 (95% CI 1.1 to 
3.6) in patients with a C. difficile positive test. All mortality 
identified occurred in-hospital.
Variables with marginal associations (p<0.01) with 
mortality are presented in table 2. A logistic regression 
including these variables, 30-day mortality, C. difficile test 
result, prior hospitalisation (30 and 90 days), critical care 
admission, tuberculosis, sex, multidrug-resistant tuber-
culosis and haematochezia was performed (table 3) for 
mortality as a dependent variable. HIV, immunosuppres-
sion and malignancy did not meet criteria for inclusion 
in the model. Multidrug-resistant tuberculosis perfectly 
predicted mortality, so the variable was dropped from 
the model (n=12). An independent risk of mortality 
in patients with diarrhoea with a C. difficile positive test 
result versus C. difficile negative test (OR 4.7, 95% CI 
2.0 to 11.2; p<0.001) was found. Clinically meaningful 
independent variables associated with mortality also 
included comorbid tuberculosis (OR 2.3, 95% CI 1.0 to 
5.0; p=0.038) and male sex (OR 2.8, 95% CI 1.1 to 7.2; 
p=0.031). Prior antibiotic exposure overall or with any 
specific antibiotic class and hospitalisation were not inde-
pendently associated with mortality.
Components of C. difficile management for the C. diffi-
cile-positive patients were assessed (n=112). Intravenous 
rehydration was widely provided (95%) but oral rehy-
dration was rarely documented (12%). Contact precau-
tions were documented for 36% of patients. Of the 21% 
of patients with a C. difficile positive result who were 
allocated to an isolation room, 16 of these 24 patients 
(67%) were also diagnosed with comorbid tuberculosis. 
Figure 1 Patient Clostridium difficile test result inclusion.
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Loperamide, contraindicated in CDI, was administered 
to 44% of all patients reviewed, which includes 41% of C. 
difficile-positive and 46% of C. difficile-negative patients. 
Loperamide was discontinued after documentation of a 
C. difficile positive result in 22% of these patients.
Twenty-nine percent of C. difficile-positive patients did 
not have documented treatment. Explanations observed 
for lack of treatment included patient improvement (n=2, 
15%), no follow-up or documentation of C. difficile test 
result during admission while the result was finalised on a 
date the patient was still hospitalised (n=8, 25%), patient 
discharge or transfer before test result finalised (n=13, 
41%) and mortality before result finalised (n=6, 19%). 
Metronidazole was the most common antimicrobial 
Figure 2 Survival curve for hospitalised patients with diarrhoea following a Clostridium difficile test. HR 2.0 (95% CI 1.1 to 
3.6).
Table 1 Patient characteristics
Clostridium difficile laboratory test result (PCR)
Positive (n=112) Negative (n=138) P values
Patient characteristic 
  Age average (years)* 47 40 <0.01
  Sex (female)* 68% 63% 0.43
  Documented HIV 71% 80% 0.07
  CD4 0.2 x10^9 cells/L † 81% 81% 0.96
  Documented tuberculosis 54% 32% <0.001
  Multidrug-resistant tuberculosis 9% 3% 0.04
Prior exposure to each C. difficile test
  Hospitalised 30 days prior to admission 52% 22% <0.001
  Hospitalised 31–90 days prior to admission 44% 23% 0.001
  30-day antibiotic exposure 83% 46% <0.001
   Penicillin 21% 11% 0.02
   Quinolone 25% 10% <0.01
   Carbapenem 22% 4% <0.001
   Cephalosporin 50% 34% <0.01
   Clindamycin 4% 0% 0.03
  31–90 days of antibiotic exposure 29% 5% <0.001
   Penicillin 12% 1% 0.001
   Quinolone 8% 1% 0.01
   Carbapenem 2% 0% 0.12
   Cephalosporin 13% 3% <0.01
   Clindamycin 0% 0%
*Mean age and gender distribution calculated for 225 individual patients, excluding patients with more than one test (102 C. difficile+; 123 C. 
difficile−).
†Of HIV+ patients, patient CD4 counts were available for 178 C. difficile test results (74 C. difficile+; 104 C. difficile−).
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therapy initiated (70%, n=78). Metronidazole strength 
was most often 400 mg (95%) for initial treatment and 
usually ordered every 8 hours (97%), consistent with the 
South African Standard Treatment Guidelines.18 Treat-
ment durations, however, varied from the 10-day guide-
line recommendation. Duration of initial metronidazole 
therapy ordered ranged from 5 to 14 days, with 10 days 
being the most commonly prescribed (45%). Metroni-
dazole orders less than or equal to 7 days were written 
for 30% of patients. C. difficile antibiotic treatment 
prescribing rates were not significantly different across 
the four hospitals.
Two patients were treated with oral vancomycin mono-
therapy for initial treatment. Vancomycin was added to or 
replaced metronidazole treatment in 14.3% of patients 
(n=16). When oral vancomycin was added, the frequency 
of administration was consistent with every 6 hours as per 
South African Standard Treatment Guidelines for CDI in 
47% of orders.18 The most common duration of vanco-
mycin was 10 days (44%) and ranged from 5 to 15 days 
(31% <7 days). All initial CDI treatment was ordered for 
oral administration. Intravenous vancomycin was added 
to metronidazole in two patients (dose 600 and 1000 mg 
once daily), but we were unable to document whether 
this vancomycin administration might have been for 
CDI management or another infection. One patient was 
changed from oral to intravenous metronidazole for 
three doses, then changed back to oral administration.
Overall, mean LOS for all hospitalisations reviewed was 
10.2±11.0 days (median 7 days, range 0–76 days). Mean 
LOS for C. difficile-positive patients discharged from the 
hospital was significantly longer (11.3±10.5 days, median 9 
days) compared with C. difficile-negative patients (8.2±8.5 
days, median=6.5 days, p=0.02). Recurrence could not 
be accurately assessed on all patients due to inconsistent 
records before and after the admission evaluated.
dIsCussIon
Although there is a wealth of data on CDI epidemiology 
and outcomes from high-resource countries, research 
from low-resource countries is sparse. This analysis and 
these data are the first examining CDI, risk factors, 
management and mortality among hospitalised patients 
in South Africa at district-level hospitals to our knowl-
edge. Understanding how CDI is currently being treated 
and which patients are at greatest risk in South Africa 
is the first step to designing and implementing quality 
improvement interventions. Prevalence of tuberculosis 
appears to be strongly associated with CDI incidence and 
to interact with demographic and other risk factors influ-
encing positive C. difficile results and mortality. Signifi-
cantly more patients in our study who tested positive for 
C. difficile had tuberculosis (p<0.001). C. difficile positive 
test result, tuberculosis and male sex were found to be 
independent risk factors for 30-day mortality in this study. 
Consistent with known CDI risk factors in high-resource 
settings, prior hospitalisation and antibiotic exposure 
were strongly associated with a positive C. difficile test 
result. Tuberculosis should be considered a risk factor 
for CDI in this population, as associations and mortality 
outcomes in this study are revelatory. Tuberculosis is a less 
critical risk factor in high-resource settings where prev-
alence is low. Targeted CDI interventions may improve 
the high mortality identified and apply to similar low-re-
source settings in the future.
A post hoc power analysis of C. difficile result and 
mortality for our sample size, 112 C. difficile positive 
results and 138 C. difficile negative results was performed. 
The calculated effect size of 0.27 indicated we had 99% 
power to detect this difference. However, it may be 
Table 2 Univariate analysis of risk factors for mortality 
found to be marginally significant (p<0.1)
Variables P values
Clostridium difficile test result 0.000
Hospitalised 30 days prior to admission 0.004




Hospitalised 90 days prior to admission 0.094
Haematochezia 0.097
Table 3 Logistic regression analysis of 30-day mortality
Variable OR SE P values 95% CI
Clostridium difficile test result 4.7 2.1 0.000 2.0 to 11.2
Hospitalised 30 days prior to admission 0.97 0.42 0.952 0.42 to 2.3
Hospitalised 90 days prior to admission 1.2 0.51 0.676 0.51 to 2.7
Critical care admission 13.8 17.9 0.044 1.0 to 176
Tuberculosis 2.3 0.91 0.038 1.0 to 5.0
Gender 2.8 1.3 0.031 1.1 to 7.2
Multidrug-resistant tuberculosis 1 – – – 
Haematochezia 0.14 0.15 0.069 0.02 to 1.2
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difficult to extrapolate these findings to patients treated 
in the private sector in South Africa, where HIV and 
tuberculosis prevalence is significantly lower. A weakness 
of this study includes the limitations of the retrospective 
design and data. The chart review included primarily 
handwritten clinical notes that occasionally required 
interpretation; assistance from local collaborators and 
study team members was essential in the data collection 
phase. The data collection was also limited to only infor-
mation included in the patient charts. For example, prior 
antibiotics and hospitalisations at institutions other than 
a patient’s local hospital would be missing, as would any 
paper records not properly combined or available during 
data collection. Furthermore, information bias from any 
missing data regarding severe infections or severe comor-
bidities such as cancer could affect the results. The study 
data are insufficient to delineate if the association of 
CDI and tuberculosis is due to disease pathogenesis or 
antibiotics administered for tuberculosis. Patients were 
unable to be evaluated for severe disease as defined by 
CDI consensus guidelines as laboratory data were often 
limited in this retrospective review. It is possible, however, 
that many patients in this study may have had severe CDI 
as evidenced by the high mortality rate of C. difficile-posi-
tive patients, independent of other variables. Despite the 
limitations of this study, we are reporting novel, needed 
and independently associated factors of significance.
The results of this study indicate key differences 
relating to CDI risk factors and mortality between high 
and low-resource countries, specifically regarding asso-
ciations of CDI to tuberculosis, sex, age and antibiotic 
exposure. First, tuberculosis is not commonly included in 
a list of risk factors for CDI, as this infection is relatively 
infrequent in high-resource countries where CDI has 
been most studied. The associations of tuberculosis and 
CDI could be related to prior healthcare exposure and 
the use of second-line tuberculosis antibiotics, including 
fluoroquinolones. A study conducted at tertiary hospi-
tals in South Korea found an increased risk of mortality 
in patients with concomitant CDI and tuberculosis, 
compared with CDI alone.19 This suggests there may be 
a pathophysiologic or antibiotic-induced relationship 
between CDI and mortality in patients with tuberculosis. 
Second, data on sex/gender differences in CDI-associ-
ated mortality are limited. Two previous studies impli-
cate male sex with CDI and complications. The first is 
a study limited to a single centre in France identifying 
male sex as a predictor of severe CDI. Another is a study 
that reported male patients with proton pump inhibitor 
use have a higher risk of CDI mortality.20 21 Tubercu-
losis incidence is higher in men in South Africa (male 
226 000 vs female 154 000) and a tendency for men to 
present for healthcare later in their disease course has 
been reported in South Africa and globally.22 23 Despite 
the propensity for CDI-related mortality in men, previous 
studies in high-resource settings report women are more 
likely to have CDI.7 24 Therefore, distinct CDI-associ-
ated risks may exist between men and women. Third, 
tuberculosis infection may also be a factor in the age of 
patients hospitalised with CDI in low-resource settings. 
The relatively young average age of patients included in 
this study likely reflects the population burden of high 
tuberculosis incidence in South Africa in the age range of 
25–44 years.22 Finally, the antibiotic exposure observed in 
this study resembles patterns observed in England prior 
to implementing prescribing patterns to control CDI, an 
element of antimicrobial stewardship.25 In addition to 
continued strengthening of antimicrobial stewardship 
efforts in South Africa, significant differences discussed 
in this manuscript highlight the need for population-tai-
lored CDI guidelines, including identification of popula-
tion-specific CDI risk factors and interventions.
Using the results of this study, clinicians and policy-
makers in areas with a high prevalence of tuberculosis 
and HIV should carefully evaluate which patients are at 
highest risk for a poor outcome from CDI and ensure 
appropriate initial treatment. The high mortality associ-
ated with CDI in this study also highlights the need for 
prompt identification, appropriate treatment, and infec-
tion prevention and control measures in populations 
with high HIV and tuberculosis prevalence. The 2010 
CDI Infectious Diseases Society of America guidelines 
recommended first-line therapy with oral metronidazole 
for mild to moderate disease. Since publication of these 
guidelines, further studies have supported the use of 
vancomycin as a first-line therapy. Subsequently, the 2017 
guidelines now restrict metronidazole to initial non-se-
vere CDI, when other therapies are contraindicated or 
unavailable.26 The majority of patients treated for CDI 
in this study received metronidazole, and were switched 
to vancomycin only if initial therapy with metronida-
zole was proven ineffective. The high mortality rate of 
patients with CDI in our study suggests that South African 
patients may benefit from first-line vancomycin therapy 
as this medication has been shown to have higher clin-
ical cure rates and significantly lower risk of mortality in 
severe CDI.27 28 If oral vancomycin therapy is not adopted 
as first-line, CDI antibiotic treatment decisions should 
include markers beyond white cell count, especially for 
immunocompromised patients and in settings where 
laboratory results are limited. Risk classifications for 
severe CDI per the European Society of Clinical Micro-
biology and Infectious Diseases include older age (>65), 
serious comorbidity, immunodeficiency and intensive 
care unit admission.29
ConClusIons
This study provides valuable information to healthcare 
providers, hospital administrators and policymakers 
regarding the demographics of hospitalised patients 
with CDI and CDI-associated patient mortality. Tubercu-
losis comorbidity should be considered a risk factor for 
CDI in addition to antibiotic use and prior healthcare 
exposure in populations with high tuberculosis and HIV 
comorbidity. Patients testing positive for C. difficile have 
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a significantly higher and independent risk of mortality 
compared with patients with diarrhoea testing negative at 
public district hospitals in South Africa. These results can 
be used to identify patients at risk of developing CDI and 
to improve the quality of care provided to patients with 
CDI in similar settings. Our results indicate improved 
CDI prevention, assessment and management is urgently 
needed in the Western Cape province.
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